Savara (SVRA)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+95.7%

$10.94 average target

$5.59+0.10 (+1.8%)Latest market snapshot · Yahoo Finance

Market cap$1.15B

Cash$174.8M

Quarterly burn$33.0M

Pipeline assets1

Short float21.0%

Latest coverage

News & Press Releases

External sources

Aug 20, 2026

Savara Announces New Employment Inducement GrantBusiness Wire

Aug 11, 2026

Savara Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire

Jul 30, 2026

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041Business Wire

Continue with BioPharma ProUnlock 5 more recent stories and press releases.

Unlock Pro

Company profile

About Savara

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.